Maculaser

Maculaser is a medical technology company on a mission to prevent blindness by targeting major retinal diseases.

[Maculaser @maculaser]

The Innovation of the Year Award by Aalto University’s School of Science was granted today for the innovation: “Maculaser - Temperature-controlled laser therapy for retinal disorders" #innovation #science #research #ophthalmology #retina #medtech #aalto #aaltouniversity

[Maculaser @maculaser]

the method provides potential means for accurate and safe therapy. This study is a major step towards developing precision laser therapy that harnesses the retina’s intrinsic stress response. We are grateful to the academic collaborations. 4/4

[Maculaser @maculaser]

We are proud to share that research using Maculaser’s technology has been published in Nature Communications: https://t.co/OQ7ex6AdNf

1/4

[Maculaser @maculaser]

activates a cellular heat shock response and induces production of therapeutic targets that can help in the management of age-related macular degeneration (hashtag#AMD) and other retinal disorders. Because the laser power is personalized to each retina’s thermal responsivity 3/4

[Maculaser @maculaser]

Maculaser is now part of PhotonMed, a €32 million European Union -funded initiative spanning 9 countries. This ambitious collaboration advances health care with cutting-edge photonics-based solutions.

Learn more:
https://t.co/xsM1jxQ8Hb

#PhotonMed #RetinalCare #Photonics

[Maculaser @maculaser]

We are pleased to announce that Aki Vartiainen joins the Maculaser team as Clinical Trial Manager. 
Aki brings strong expertise to our team, having worked on over 20 clinical trials, including First-In-Human and post-market studies. Welcome to #Maculaser, Aki!#ClinicalTrials

[Maculaser @maculaser]

Maculaser has been granted a Japanese patent for its method and device for determining changes in retinal and/or brain temperature. This is Maculaser’s first patent outside the EU and US and marks a significant milestone for the company. #retina #patents #maculaser #ophthalmology

[Maculaser @maculaser]

Maculaser has been awarded a 400kEUR Deep Tech Accelerator grant from Business Finland. This brings our total private and public funding for 2023 to 1MEUR and company's overall funding to 3MEUR. We thank our funders for their support in advancing our mission to develop and commercialize novel retina treatments, ultimately significantly enhancing clinical outcomes.
#DeepTech #MedTech #Startup #Retina #MacularDegeneration #DiabeticRetinopathy

https://t.co/UGxdt78TWQ

[Maculaser @maculaser]

Congratulations to Mooud Amirkavei on her exceptional defense of her PhD thesis titled "Unraveling the Effects of Hormetic Heat Shock as a Treatment for Age-Related Macular Degeneration." Her research holds utmost relevance, particularly in the context of emerging therapies for dry #AMD .

#maculardegeneration #research #aaltouniversity #karolinskaInstitutet #maculaser

https://t.co/v5VuGkeYFn

[Maculaser @maculaser]

Maculaser, a company developing treatments for retinal disorders that affect millions of people worldwide, was awarded the Instrumentarium Science Foundation Silmu grant (50 k€) intended to support scientific entrepreneurship. Thank you @tiedesaatio for supporting us!

[Maculaser @maculaser]

Maculaser's novel temperature-controlled subthreshold laser therapy and method for treating diabetic macular edemas is currently being presented at major US based #PhotonicsWest #BIOS conference by our partner company Modulight! #ophthalmology #retina #maculaser

[Modulight® Corporation @modulight]

On Sunday, the presentations at #PhotonicsWest #BIOS continue! Check out these two:

Welcome to listen and discuss! More presentations coming up on #OPTO and #QUANTUMWEST

#killcancer #modulight #oncology #ophthalmology #bladdercancer #drugdiscovery #laserfamily

[Maculaser @maculaser]

A novel thermal dosimetry -controlled subthreshold laser treatment modality might change the treatment scheme for many common retinal diseases like age-related macular degeneration.
#maculardegeneration #maculaser

https://t.co/erw7mzlSUW

[Maculaser @maculaser]

#Maculaser’s CSO Teemu Turunen presented the results of our clinical usability trial in Visionarium XX, a conference for wide-scope vision research. Important milestone on our way to clinical trials investigating the efficacy of the laser-induced heat shock therapy of the #retina

[Maculaser @maculaser]

#Maculaser and Vinberg Lab in University of Utah have started a collaborative project to develop novel method and technology that can enable early detection and monitoring the progression of Age-related Maculaser Degeneration (#AMD). https://t.co/EKl9j5Hpww

#retina #diagnostics

[Maculaser @maculaser]

Meet the #Maculaser team in Denver at #ARVO2022! Check our poster on 10:00 AM - 12:00 PM, Wednesday, May 4 (poster board Number F0219): ERG-based thermal dosimetry for subthreshold retinal laser therapy in anaesthetized pigs. #retina #ophthalmology

https://t.co/HgA8joUcYx

[Maculaser @maculaser]

A novel method used by Maculaser has been published in a distinguished peer reviewed biomedical journal.

https://t.co/eaeWJiXvBt

Research continues to investigate the effect of temperature-controlled laser treatment on heat shock response and autophagy! #Ophthalmology

[Maculaser @maculaser]

#Maculaser seed finance round is now completed with #Businessfinland support. The round totaled 2.1 MEUR, enabling fast development of novel temperature-controlled #retina #laser and planned #clinicaltrials #medtech #ophthalmology #maculardegeneration #diabeticretinopathy

[Maculaser @maculaser]

We are excited to announce a major milestone, the closing of our seed funding round of 1.2MEUR led by @Innovestor ventures with participation from institutional and private investors. Thank you for your support on our journey to prevent blindness. #startup #funding #medtech

[Innovestor @Innovestor]

🥁 Announcing our lead investment into Finnish #medtech startup @maculaser who raised a €1,2 million round! 🥁 Excited to onboard on the fight against combating blinding diseases with your new laser therapy #technology!

Read in English on our website: https://t.co/dGBg8HbJU9

[Health Capital Helsinki @HealthHelsinki]

#Helsinki #medtech #startup @Maculaser introduces temperature-control to non-damaging #retina laser treatment to cure retinal diseases, the leading cause for blindness. The startup takes part in #HealthIncubatorHelsinki.

Read Maculaser's story ➡️ https://t.co/Qr4LIAtX8i